Testing effectiveness (Phase 2)Active Not RecruitingNCT04925544
What this trial is testing
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Who this might be right for
Nasopharyngeal CancerEpstein-Barr Virus Related Carcinoma
Stanford University 13